NCT02736695View on ClinicalTrials.gov

Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia and Frontotemporal Dementia

NACompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

August 1, 2024

Study Completion Date

August 1, 2024

Conditions
Primary Progressive AphasiaBehavioral Variant of Frontotemporal DementiaFrontotemporal Dementia, Behavioral Variant
Interventions
DRUG

F-18 AV 1451

Tau binding agent

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT02736695 - Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia and Frontotemporal Dementia | Biotech Hunter | Biotech Hunter